runcaciguat   Click here for help

GtoPdb Ligand ID: 12359

Synonyms: BAY 1101042 | BAY-1101042 | BAY1101042 | compound 45 [PMID: 33872507]
PDB Ligand
Compound class: Synthetic organic
Comment: Runcaciguat (BAY 1101042) is an oral, selective soluble guanylyl cyclase (sGC) activator [1]. It is suitable for once-daily dosing.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 66.4
Molecular weight 487.09
XLogP 6.76
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC(=O)C[C@H](c1ccc(c(c1)NC(=O)[C@@H]([C@H](C(F)(F)F)C)c1ccc(cc1)Cl)Cl)C1CC1
Isomeric SMILES C[C@H]([C@@H](c1ccc(cc1)Cl)C(=O)Nc1c(ccc(c1)[C@@H](CC(=O)O)C1CC1)Cl)C(F)(F)F
InChI InChI=1S/C23H22Cl2F3NO3/c1-12(23(26,27)28)21(14-4-7-16(24)8-5-14)22(32)29-19-10-15(6-9-18(19)25)17(11-20(30)31)13-2-3-13/h4-10,12-13,17,21H,2-3,11H2,1H3,(H,29,32)(H,30,31)/t12-,17+,21+/m1/s1
InChI Key NCRMKIWHFXSBGZ-CNBXIYLPSA-N
No information available.
Summary of Clinical Use Click here for help
Runcaciguat was advanced to clinical evaluation for potential to treat chronic kidney disease and non-proliferative diabetic retinopathy. A Phase 1 trial chronic kidney disease patients was terminated when the developer (Bayer) changed their development priorities.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04820621 Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment Phase 1 Interventional Bayer
NCT04507061 Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels. Phase 2 Interventional Bayer The CONCORD trial
NCT04722991 Non-proliferative Diabetic Retinopathy Treated With Runcaciguat Phase 2 Interventional Bayer The NEON trial